^
    Back
    Association details:
    Biomarker:KIF5B-RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

    Excerpt:
    ...Group A: KIF5B/RET or related variant RET fusions....
    Trial ID:
    NCT01639508
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    IASLC-TTLC 2021
    Title:

    P08.01: Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors

    Published date:
    02/19/2021
    Excerpt:
    We present here a case of TKI resistance in a patient with KIF5B-RET fusion advanced NSCLC. Following progression on cabozantinib, he was started on selpercatinib. At the time of initial diagnosis molecular profiling revealed a KIF5B-RET fusion...he initiated cabozantinib, remained on therapy for 4 months with subsequent progression at multiple sites. He was treated with selpercatinib for 23 months before oligometastatic progression. Molecular analysis via cell-free DNA again revealed KIF5B-RET fusion without any alterations known to cause TKI resistance.